- Home
- EDSA vs TLPH Comparison
EDSA vs TLPH Comparison
Compare EDSA & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- TLPH
- Stock Information
- Founded
- EDSA 2015
- TLPH 2005
- Country
- EDSA Canada
- TLPH United States
- Employees
- EDSA N/A
- TLPH N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- EDSA Health Care
- TLPH Health Care
- Exchange
- EDSA Nasdaq
- TLPH Nasdaq
- Market Cap
- EDSA 6.1M
- TLPH 12.7M
- IPO Year
- EDSA N/A
- TLPH 2011
- Fundamental
- Price
- EDSA $1.73
- TLPH $0.64
- Analyst Decision
- EDSA Strong Buy
- TLPH Strong Buy
- Analyst Count
- EDSA 1
- TLPH 2
- Target Price
- EDSA $21.00
- TLPH $4.50
- AVG Volume (30 Days)
- EDSA 30.6K
- TLPH 95.8K
- Earning Date
- EDSA 02-07-2025
- TLPH 11-13-2024
- Dividend Yield
- EDSA N/A
- TLPH N/A
- EPS Growth
- EDSA N/A
- TLPH N/A
- EPS
- EDSA N/A
- TLPH N/A
- Revenue
- EDSA N/A
- TLPH $281,000.00
- Revenue This Year
- EDSA N/A
- TLPH N/A
- Revenue Next Year
- EDSA N/A
- TLPH N/A
- P/E Ratio
- EDSA N/A
- TLPH N/A
- Revenue Growth
- EDSA N/A
- TLPH N/A
- 52 Week Low
- EDSA $1.55
- TLPH $0.60
- 52 Week High
- EDSA $5.99
- TLPH $1.61
- Technical
- Relative Strength Index (RSI)
- EDSA 31.51
- TLPH 39.75
- Support Level
- EDSA $1.73
- TLPH $0.60
- Resistance Level
- EDSA $1.99
- TLPH $0.76
- Average True Range (ATR)
- EDSA 0.19
- TLPH 0.07
- MACD
- EDSA 0.02
- TLPH -0.00
- Stochastic Oscillator
- EDSA 18.00
- TLPH 17.65
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.